inomax
nitric oxide -
catapres
clinect nz pty limited - clonidine hydrochloride 150 µg/ml - solution for injection - 150 mcg/ml - active: clonidine hydrochloride 150 µg/ml excipient: hydrochloric acid sodium chloride water for injection - parenteral catapres is indicated for the treatment of hypertensive crises, slow parenteral administration is especially suitable due to the rapid onset of action.
catapres
clinect nz pty limited - clonidine hydrochloride 150ug - tablet - 150 mcg - active: clonidine hydrochloride 150ug excipient: calcium hydrogen phosphate colloidal silicon dioxide lactose monohydrate maize starch povidone stearic acid
catapres-tts
carsl consulting - clonidine 2.5mg - transdermal patch - 2.5 mg - active: clonidine 2.5mg excipient: calcium stearate - catapres-tts is indicated for the treatment of mild to moderate hypertension. it can be used as monotherapy or concomitantly with other antihypertensive agents if required to enhance hypotensive effect.
catapres-tts
carsl consulting - clonidine 5mg - transdermal patch - 5 mg - active: clonidine 5mg excipient: calcium stearate - catapres-tts is indicated for the treatment of mild to moderate hypertension. it can be used as monotherapy or concomitantly with other antihypertensive agents if required to enhance hypotensive effect.
catapres-tts
carsl consulting - clonidine 7.5mg - transdermal patch - 7.5 mg - active: clonidine 7.5mg excipient: calcium stearate - catapres-tts is indicated for the treatment of mild to moderate hypertension. it can be used as monotherapy or concomitantly with other antihypertensive agents if required to enhance hypotensive effect.
clonidine (teva)
teva pharma (new zealand) limited - clonidine hydrochloride 25ug - tablet - 25 mcg - active: clonidine hydrochloride 25ug excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose pregelatinised maize starch purified talc sodium starch glycolate - the prophylactic management of migraine or recurrent vascular headaches in adult patients. the management of vasomotor conditions commonly associated with the menopause and characterised by flushing.
dixarit
boehringer ingelheim (nz) limited - clonidine hydrochloride 25ug - tablet - 25 mcg - active: clonidine hydrochloride 25ug excipient: acacia amylodextrin calcium hydrogen phosphate dihydrate carnauba wax colloidal silicon dioxide indigo carmine lactose monohydrate macrogol 6000 magnesium stearate maize starch methyl hydroxybenzoate povidone propyl hydroxybenzoate purified talc sucrose titanium dioxide white beeswax
survanta
abbvie limited - bovine lung lipids 25 mg/ml (total phospholipids); colfosceril palmitate 11 mg/ml - 15.5 mg/ml (disaturated phosphatidylcholine); palmitic acid 1.4 mg/ml - 3.5 mg/ml (free fatty acid); tripalmitin 0.5 mg/ml - 1.75 mg/ml (triglycerides) - intratracheal suspension - 25 mg/ml - active: bovine lung lipids 25 mg/ml (total phospholipids) colfosceril palmitate 11 mg/ml - 15.5 mg/ml (disaturated phosphatidylcholine) palmitic acid 1.4 mg/ml - 3.5 mg/ml (free fatty acid) tripalmitin 0.5 mg/ml - 1.75 mg/ml (triglycerides) excipient: sodium chloride water for injection - survanta is indicated for prevention and treatment ("rescue") of respiratory distress syndrome (rds) (hyaline membrane disease) in premature infants. survanta significantly reduces the incidence of rds, mortality due to rds and air leak complications.
xylapan 20 mg/ml solution for injection
vetoquinol uk limited - xylazin hydrochloride - solution for injection - 20 mg/ml - xylazine - bovine, canine, equine - food, feline - neurological preparations